胃癌的抗血管生成治疗研究进展

Advances in antiangiogenic therapy of gastric cancer

肿瘤血管生成在癌细胞增殖和转移中起重要作用,在众多相关的临床试验中,雷莫芦单抗(Ramucirumab)不仅可以单独使用,还可以联合紫杉醇作为二线化疗药物来延长总体生存期。此外,阿帕替尼(Apatinib)作为三线或后续的治疗方案可延长晚期胃癌患者的生存期。诸多研究将阿帕替尼与细胞毒剂联合用于全身系统性化学治疗或维持治疗,为胃癌的早期治疗提供更多选择。抗血管生成疗法不仅要结合化学疗法,还要结合免疫检查点抑制剂进行进一步研究,为改善胃癌患者的生存率提供希望。本文旨在总结抗血管生成治疗胃癌的最新进展,并讨论经临床试验检测的抗血管生成药物在治疗该疾病中的实用性。

Tumor angiogenesis plays an important role in the proliferation and metastasis of cancer cells. In many related clinical experiments, Ramucirumab can not only be used alone, but also can be used in combination with Paclitaxel as a second-line chemotherapy drug to prolong the overall survival period.In addition, Apatinib as a third-line or follow-up treatment can prolong the survival of patients with advanced gastric cancer. Many advances have studied the combination of Apatinib and cytotoxic agents for systemic chemotherapy or maintenance therapy, providing more options for early treatment of gastric cancer. Antiangiogenic therapy should not only be combined with chemotherapy, but also with immunosuppressive agents for further study, so as to provide hope for improving the survival rate of gastric cancer patients. This review is to summarize the latest progress of antiangiogenic therapy for gastric cancer, and to discuss the practicability of antiangiogenic drugs in the treatment of gastric cancer.